Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
MTEM - Molecular Templates Inc
$11.05
-0.04(-0.36%)9:00:00 PM 1/15/2021
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies. The company's lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted conditioning regimens to enhance the hematopoietic stem cell transplant process. Molecular Templates, Inc. is headquartered in Austin, Texas.
Stock Chart

Summary:

  • MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    12/21/2020MTEM
    Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

    Phase 1 Study Dose Escalation Ongoing in All HER2 Positive Tumor Types HER2 Positive Breast Cancer Expansion Cohort Planned to be Initiated in 1H21 Expansion Cohorts in Additional Tumors Types to Begin When MTD or Recommended Phase 2 Dose is ReachedAUSTIN, Texas, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted ...

    12/19/2020MTEM
    Is MTEM A Good Stock To Buy Now According To Hedge Funds?

    Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 817 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

    12/1/2020MTEM
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Templates, Inc. - MTEM

    NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Molecular Templates, Inc. (“Molecular” or the “Company”) (NASDAQ: MTEM).   Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.  The investigation concerns whether Molecular and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining t...

    11/24/2020MTEM
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Templates, Inc. - MTEM

    NEW YORK, NY / ACCESSWIRE / November 23, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Molecular Templates, Inc.

    11/22/2020MTEM
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molecular Templates, Inc. - MTEM

    NEW YORK, Nov. 21, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Molecular Templates, Inc. (“Molecular” or the “Company”) (NASDAQ: MTEM).   Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.  The investigation concerns whether Molecular and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining t...

    11/16/2020MTEM
    Molecular Templates to Participate in Upcoming Virtual Investor Conferences

    AUSTIN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it will deliver presentations and participate in 1on1 meetings at the Stifel 2020 Virtual Healthcare Conference a...

    11/12/2020MTEM
    Insider Buys Molecular Templates Shares

    Molecular Templates Inc (NASDAQ:MTEM) was trading 11.6% higher from the previous closing price. A Form 4 filing filed with the SEC on Wednesday, November 11 showed that Biotech Target N V bought 80,000 shares at $9.05 on Monday, Nov 09, and bought 80,000 shares at $9.16 on Tuesday, Nov 10.The transaction moved the executive's stake in Molecular Templates Inc. to 5,855,331 shares.Why Insider Transactions Are Important? While transactions from an insider shouldn't be used as the sole item to make ...

    11/10/2020MTEM
    Oppenheimer Sees These 3 Stocks Skyrocketing Over 100%

    The U.S. presidential election has come to a close, and Wall Street isn’t opposed to the administration change. Last week saw the S&P 500 notch its second-best performance during an election week on record, even as Trump’s chances of getting re-elected became slimer and slimer.Weighing in for Oppenheimer, Chief Investment Strategist John Stoltzfus noted, “What appears clear so far is that the equity markets are not averse to a change of administration stateside at least so long as the Republican...